Asia Pac Allergy.  2011 Apr;1(1):2-11. 10.5415/apallergy.2011.1.1.2.

Clinical applications of drug desensitization in the Asia-Pacific region

• Thong BY

• KMID: 2397139
• DOI: http://doi.org/10.5415/apallergy.2011.1.1.2

Abstract

Drug desensitization is the induction, within hours to days, of a temporary state of tolerance to a drug which the patient has developed a hypersensitivity reaction to. It may be used for IgE and non-IgE mediated allergic reactions, and certain non-allergic reactions. The indication for desensitization is where no alternative medications are available for the treatment of that condition, and where the benefits of desensitization outweigh the risks. Desensitization is a therapeutic modality for drug allergy (similar to allergen specific immunotherapy for allergic rhinitis and insect venom anaphylaxis). In contrast, the drug provocation test is a diagnostic modality used to confirm or refute the diagnosis of drug allergy. This review discusses the clinical applications of desensitization for the treatment of common infectious, metabolic and cardiovascular diseases, and oncological conditions in the Asia-Pacific region.

Keyword

Anaphylaxis; Desensitization; Drug hypersensitivity; Stevens Johnson syndrome; Toxic epidermal necrolysis

MeSH Terms

Anaphylaxis
Cardiovascular Diseases
Diagnosis
Drug Hypersensitivity
Humans
Hypersensitivity
Immunoglobulin E
Immunotherapy
Insects
Rhinitis, Allergic
Stevens-Johnson Syndrome
Venoms
Immunoglobulin E
Venoms

Reference

1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004. 113:832–836.

2. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011. 71:684–700.

3. Thong BY. Update on the management of antibiotic allergy. Allergy Asthma Immunol Res. 2010. 2:77–86.

4. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, Campi P, Sanz ML, Castells M, Demoly P, Pichler WJ. European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy. 2010. 65:1357–1366.

5. Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am. 2009. 29:585–606.

6. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P. European Network for Drug Allergy (ENDA). EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003. 58:854–863.

7. Woo HY, Kim YS, Kang NI, Chung WC, Song CH, Choi IW, Choi IH, Lee HK. Mechanism for acute oral desensitization to antibiotics. Allergy. 2006. 61:954–958.

8. Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol. 2005. 138:29–39.

9. Odom S, Gomez G, Kovarova M, Furumoto Y, Ryan JJ, Wright HV, Gonzalez-Espinosa C, Hibbs ML, Harder KW, Rivera J. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J Exp Med. 2004. 199:1491–1502.

10. Malaviya R, Uckun FM. Role of STAT6 in IgE receptor/FcepsilonRI-mediated late phase allergic responses of mast cells. J Immunol. 2002. 168:421–426.

11. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol. 2005. 94:575–580.

12. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003. 139:683–693.

13. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy. 2007. 37:989–999.

14. Gruchalla RS, Pesenko RD, Do TT, Skiest DJ. Sulfonamide-induced reactions in desensitized patients with AIDS--the role of covalent protein haptenation by sulfamethoxazole. J Allergy Clin Immunol. 1998. 101:371–378.

15. Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology. 2004. 209:29–32.

16. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004. 328:434.

17. McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma. Detection by oral challenge. J Allergy Clin Immunol. 1972. 50:198–207.

18. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003. 111:913–921.

19. Arm JP, Austen KF. Leukotriene receptors and aspirin sensitivity. N Engl J Med. 2002. 347:1524–1526.

20. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B₄ production after aspirin desensitization. J Allergy Clin Immunol. 1995. 96:148–156.

21. Nasser SM, Patel M, Bell GS, Lee TH. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1995. 151:1326–1330.

22. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994. 265:956–959.

23. Perez-G M, Melo M, Keegan AD, Zamorano J. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J Immunol. 2002. 168:1428–1434.

24. Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010. 126:738–744.

25. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004. 292:3017–3023.

26. Page NA, Schroeder WS. Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy. Ann Pharmacother. 2007. 41:61–67.

27. Joint Task Force on Practice Parameters. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010. 105:259–273.

28. Allain H, Chevrant-Breton J, Beneton C, Bousser AM, Bentue-Ferrer D, Mazeas D, Van den Driessche J. Undesirable dermatologic results of drugs. Result of a drug monitoring survey. Ann Med Interne (Paris). 1983. 134:530–536.

29. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15 438 consecutive inpatients, 1975 to 1982. JAMA. 1986. 256:3358–3363.

30. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991. 266:2847–2851.

31. Rademaker M, Oakley A, Duffill MB. Cutaneous adverse drug reactions in a hospital setting. N Z Med J. 1995. 108:165–166.

32. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India. J Postgrad Med. 2001. 47:95–99.

33. Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol. 2003. 90:342–347.

34. Park CS, Kim TB, Kim SL, Kim JY, Yang KA, Bae YJ, Cho YS, Moon HB. The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea. Pharmacoepidemiol Drug Saf. 2008. 17:919–925.

35. Burrows JA, Toon M, Bell SC. Antibiotic desensitization in adults with cystic fibrosis. Respirology. 2003. 8:359–364.

36. Turvey SE, Cronin B, Arnold AD, Dioun AF. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol. 2004. 92:426–432.

37. Sullivan TJ, Yecies LD, Shatz GS, Parker CW, Wedner HJ. Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics. J Allergy Clin Immunol. 1982. 69:275–282.

38. Borish L, Tamir R, Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol. 1987. 80:314–319.

39. Win PH, Brown H, Zankar A, Ballas ZK, Hussain I. Rapid intravenous cephalosporin desensitization. J Allergy Clin Immunol. 2005. 116:225–228.

40. Ghosal S, Taylor CJ. Intravenous desensitization to ceftazidime in cystic fibrosis patients. J Antimicrob Chemother. 1997. 39:556–557.

41. Papakonstantinou G, Bogner JR, Hofmeister F, Hehlmann R. Cefotaxime desensitization. Clin Investig. 1993. 71:165–167.

42. Poston SA, Jennings HR, Poe KL. Cefazolin tolerance does not predict ceftriaxone hypersensitivity: unique side chains precipitate anaphylaxis. Pharmacotherapy. 2004. 24:668–672.

43. Wilson DL, Owens RC Jr, Zuckerman JB. Successful meropenem desensitization in a patient with cystic fibrosis. Ann Pharmacother. 2003. 37:1424–1428.

44. Confino-Cohen R, Goldberg A, Lang R. Prolonged continuous i.v. "desensitization" in Tienam hypersensitivity. Allergy. 1997. 52:683–684.

45. Gorman SK, Zed PJ, Dhingra VK, Ronco JJ. Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia. Ann Pharmacother. 2003. 37:513–516.

46. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol. 2006. 6:476–481.

47. Nair N, Wares F, Sahu S. Tuberculosis in the WHO South-East Asia Region. Bull World Health Organ. 2010. 88:164.

48. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006. 5:231–249.

49. Lee AY, Jung SY. Two patients with isoniazid-induced photosensitive lichenoid eruptions confirmed by photopatch test. Photodermatol Photoimmunol Photomed. 1998. 14:77–78.

50. Leenutaphong V, Sivayathorn A, Suthipinittharm P, Sunthonpalin P. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol. 1993. 32:428–431.

51. Kuaban C, Bercion R, Koulla-Shiro S. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon. East Afr Med J. 1997. 74:474–477.

52. Barbaud A. Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am. 2009. 29:517–535.

53. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001. 45:321–328.

54. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004. 59:809–820.

55. Lochmatter P, Zawodniak A, Pichler WJ. In vitro tests in drug hypersensitivity diagnosis. Immunol Allergy Clin North Am. 2009. 29:537–554.

56. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010. 10:621–629.

57. Levene GM, Withers AF. Anaphylaxis to streptomycin and hyposensitization (parasensitization). Trans St Johns Hosp Dermatol Soc. 1969. 55:184–188.

58. Holland CL, Malasky C, Ogunkoya A, Bielory L. Rapid oral desensitization to isoniazid and rifampin. Chest. 1990. 98:1518–1519.

59. Buergin S, Scherer K, Häusermann P, Bircher AJ. Immediate hypersensitivity to rifampicin in 3 patients: diagnostic procedures and induction of clinical tolerance. Int Arch Allergy Immunol. 2006. 140:20–26.

60. Matz J, Borish LC, Routes JM, Rosenwasser LJ. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med. 1994. 149:815–817.

61. Numata I, Ogawa M, Nagasawa S, Murata A, Shimoide H. Desensitization of PAS hypersensitivity with Pascon, a compound of PAS and Scormin. Iryo. 1970. 24:567–570.

62. Kobashi Y, Okimoto N, Matsushima T, Abe T, Nishimura K, Shishido S, Kawahara S, Shigeto E, Takeyama H, Kuraoka T. Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis. Kekkaku. 2000. 75:699–704.

63. Kim JH, Kim HB, Kim BS, Hong SJ. Rapid oral desensitization to isoniazid, rifampin, and ethambutol. Allergy. 2003. 58:540–541.

64. Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol. 2008. 121:826–832.

65. Carr A, Cooper DA. Volberding P, Jacobsen MA, editors. Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS clinical review 1995/1996. 1996. New York: Marcel Dekker;65–98.

66. Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev. 2007. CD005646.

67. Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol. 1994. 93:1001–1005.

68. Caumes E, Guermonprez G, Lecomte C, Katlama C, Bricaire F. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol. 1997. 133:465–469.

69. Nguyen MT, Weiss PJ, Wallace MR. Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS. 1995. 9:573–575.

70. Palusci VJ, Kaul A, Lawrence RM, Haines KA, Kwittken PL. Rapid oral desensitization to trimethoprim-sulfamethoxazole in infants and children. Pediatr Infect Dis J. 1996. 15:456–460.

71. Douglas R, Spelman D, Czarny D, O'Hehir RE. Successful desensitization of two patients who previously developed Stevens-Johnson syndrome while receiving trimethoprim-sulfamethoxazole. Clin Infect Dis. 1997. 25:1480.

72. Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, Moore MA, Brothers CH, Scott TR. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004. 38:2171–2172.

73. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002. 359:727–732.

74. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002. 359:1121–1122.

75. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008. 358:568–579.

76. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998. 20:1071–1092.

77. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008. 128:35–44.

78. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003. 83:1–9.

79. Kohli-Pamnani A, Huynh P, Lobo F. Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. Ann Allergy Asthma Immunol. 2006. 96:620–623.

80. Marcos Bravo MC, Ocampo Hermida A, Martínez Vilela J, Pérez Rodríguez MT, Gavilán Montenegro MJ, Arenas Villarroel LJ, Miralles Alvarez C, Rodríguez Dasilva A, Martínez Vázquez C. Hypersensitivity reaction to darunavir and desensitization protocol. J Investig Allergol Clin Immunol. 2009. 19:250–251.

81. Phillips EJ, Kuriakose B, Knowles SR. Efavirenz-induced skin eruption and successful desensitization. Ann Pharmacother. 2002. 36:430–432.

82. Shahar E, Moar C, Pollack S. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction. AIDS. 2005. 19:451–452.

83. DeSimone JA, Ojha A, Pathak R, Cohn J. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man. Clin Infect Dis. 2004. 39:e110–e112.

84. Demoly P, Messaad D, Trylesinski A, Faucherre V, Fabre J, Reynes J, Delmas C, Dohin E, Godard P, Bousquet J. Nelfinavir-induced urticaria and successful desensitization. J Allergy Clin Immunol. 1998. 102:875–876.

85. Carr A, Penny R, Cooper DA. Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS). J Allergy Clin Immunol. 1993. 91:683–685.

86. Davatchi F. Rheumatic diseases in the APLAR region. APLAR J Rheumatol. 2006. 9:5–10.

87. Padang C, Muirden KD, Schumacher HR, Darmawan J, Nasution AR. Characteristics of chronic gout in Northern Sulawesi, Indonesia. J Rheumatol. 2006. 33:1813–1817.

88. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997. 56:22–26.

89. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Chung SH, Kim CG, Choe JY, Lee SW, Chung WT, Song GG. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005. 20:1029–1033.

90. Inokuchi T, Tsutsumi Z, Takahashi S, Ka T, Moriwaki Y, Yamamoto T. Increased frequency of metabolic syndrome and its individual metabolic abnormalities in Japanese patients with primary gout. J Clin Rheumatol. 2010. 16:109–112.

91. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, Lin CM, Chen HW, Yu KH. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010. 49:141–146.

92. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981. 40:245–249.

93. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005. 102:4134–4139.

94. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009. 19:704–709.

95. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R. JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008. 9:1617–1622.

96. Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, Kang HR. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011. 03. 10. [Epub ahead of print].

97. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Chang IJ, Cho SH, Min KU, Kim SH, Lee KW. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011. 02. 04. [Epub ahead of print].

98. Meyrier A. Desensitisation in a patient with chronic renal disease and severe allergy to allopurinol. Br Med J. 1976. 2:458.

99. Walz-LeBlanc BA, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum. 1991. 34:1329–1331.

100. Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med. 1992. 93:299–302.

101. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001. 44:231–238.

102. Unsworth J, Blake DR, d'Assis Fonseca AE, Beswick DT. Desensitisation to allopurinol: a cautionary tale. Ann Rheum Dis. 1987. 46:646.

103. Jansen TL, Richette P, Perez-Ruiz F, Tausche AK, Guerne PA, Punzi L, Leeb B, Barskova V, Uhlig T, Pimentão J, Zimmermann-Górska I, Pascual E, Bardin T, Doherty M. International position paper on febuxostat. Clin Rheumatol. 2010. 29:835–840.

104. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentäo J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006. 65:1312–1324.

105. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G. British Society for Rheumatology and British Health Professionals in Rheumatology Standards. Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007. 46:1372–1374.

106. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci. 2007. 4:83–93.

107. Lee CM, Huxley RR, Lam TH, Martiniuk AL, Ueshema H, Pan WH, Welborn T, Woodward M. Asia Pacific Cohort Studies Collaboration. Prevalence of diabetes mellitus and population attributable fractions for coronary heart disease and stroke mortality in the WHO South-East Asia and Western Pacific regions. Asia Pac J Clin Nutr. 2007. 16:187–192.

108. Goh CL. Psoriasiform drug eruption due to glibenclamide. Australas J Dermatol. 1987. 28:30–32.

109. Koca R, Altinyazar HC, Yenidünya S, Tekin NS. Psoriasiform drug eruption associated with metformin hydrochloride: a case report. Dermatol Online J. 2003. 9:11.

110. Fox GN, Harrell CC, Mehregan DR. Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature. Cutis. 2005. 76:41–45.

111. Adams BB, Gadenne AS. Glipizide-induced pigmented purpuric dermatosis. J Am Acad Dermatol. 1999. 41:827–829.

112. Chitturi S, Le V, Kench J, Loh C, George J. Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci. 2002. 47:1107–1110.

113. Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow H, Freise C, Lee WM, Bass NM. Acute Liver Failure Study Group. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci. 2000. 45:549–553.

114. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009. 54:516–523.

115. Heinzerling L, Raile K, Rochlitz H, Zuberbier T, Worm M. Insulin allergy: clinical manifestations and management strategies. Allergy. 2008. 63:148–155.

116. Mattson JR, Patterson R, Roberts M. Insulin therapy in patients with systemic insulin allergy. Arch Intern Med. 1975. 135:818–821.

117. Tuboi M, Tsuchiya T, Taguchi R, Tanaka Y, Iwasaki Y, Hashimoto K, Kakizaki S, Okada S, Shimizu H, Mori M. Insulin allergy whose local/systemic reactions were reduced by desensitization with long-acting insulin analog, glargine. Nippon Naika Gakkai Zasshi. 2010. 99:133–135.

118. Hara M, Izumida Y, Sato N, Ohashi K, Osuga J, Tobe K, Tsukamoto K, Kadowaki T. Successful desensitization by glargine administration in a patient with insulin allergy: a case report. Diabetes Res Clin Pract. 2009. 84:e48–e49.

119. Yokoyama H, Fukumoto S, Koyama H, Emoto M, Kitagawa Y, Nishizawa Y. Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Pract. 2003. 61:161–166.

120. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med. 1997. 36:575–578.

121. Jang JH, Kim YG, Lee AY. Successful desensitization of a case of anaphylaxis to insulin. Korean J Dermatol. 1998. 36:1146–1148.

122. Park KW, Park HS, Park SW, Jang CS, Whan CC, Hong SB, Kim YS, Park W, Song JS, Choi SW. A case of anaphylaxis to human recombinant insulin treated by desensitization. Korean J Med. 2002. 62:204–208.

123. Hong JH, Lee JH, Shin JH, Kim DP, Ko BS, Kim BJ, Kim HJ, Park KS. Maintenance of insulin therapy by desensitization in insulin allergy patient. Korean Diabetes J. 2008. 32:529–531.

124. Kim MH, Lim KH, Park HK, Kim BK, Kang MK, Kwon JW, Kim TW, Jung JW, Lee SH, Lee SM, Kim SH, Park HW, Kang HR, Chang YS, Kim SS, Cho SH, Min KU, Kim YY. A case of change of insulin-specific antibodies following desensitization in insulin hypersensitivity patients. Korean J Asthma Allergy Clin Immunol. 2010. 30:63–67.

125. Chng HH, Leong KP, Loh KC. Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization. Allergy. 1995. 50:984–987.

126. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary diseas e in a population-based study. Int J Epidemiol. 1999. 28:717–722.

127. Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart J, Gladysz U, Malolepszy J, Szczeklik A. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. 2003. 58:1064–1066.

128. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax. 2002. 57:569–574.

129. Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2010. 10:280–290.

130. Pfaar O, Klimek L. Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Curr Opin Allergy Clin Immunol. 2006. 6:161–166.

131. Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000. 105:997–1001.

132. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol. 2005. 95:509–510.

133. Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA, Mihalcsik L, Gavazzi A. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol. 2008. 101:786–789.

134. Jim MH, Yung AS, Tang GK, Fan KY, Chow WH. Successful use of endothelial progenitor cell capture stents in a coronary artery disease patient with aspirin hypersensitivity who failed initial aspirin desensitization. Int J Cardiol. 2010. 06. 08. [Epub ahead of print].

135. Yoo KY. Cancer prevention in the Asia Pacific region. Asian Pac J Cancer Prev. 2010. 11:839–844.

136. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008. 122:574–580.

137. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009. 124:1259–1266.